Recent Finacing
Recent Raise
Delenex Therapeutics develops topically applied PENTRA® antibody fragments (PENTRA Bodies), including DLX105, an anti‑TNFα scFv for dermatologic and inflammatory indications from Schlieren, Switzerland.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors